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Abstract 
Introduction: Little is known about how modifiable lifestyle factors interact with the epigenome to 
influence disease. Body mass index (BMI, weight kg/height m2) and physical activity are associated with 
postmenopausal breast cancer, but the mechanisms are not well-understood. We hypothesized that 
BMI or physical activity may modify the association between markers of global DNA methylation and 
postmenopausal breast cancer risk.  
Methods: Resources from a population-based case-control study (~1300 postmenopausal women) 
were used to construct logistic regression models. We explored whether the association between 
breast cancer and global methylation, assessed using the luminometric methylation assay (LUMA) and 
long interspersed elements-1 (LINE-1) methylation in white blood cell DNA, was modified by BMI or 
recreational physical activity (RPA).  
Results: The LUMA-breast cancer association was modified by BMI (multiplicative p=0.03) and RPA 
(p=0.004). Non-obese women in the highest quartile of LUMA experienced a greater than two-fold 
increased risk of postmenopausal breast cancer (BMI<25kg/m2: OR=2.16; 95% CI=1.35, 3.57 and BMI 
25-29.9kg/m2: OR=2.96; 95% CI=1.69, 5.19) compared to women in the lowest LUMA quartile. Similar 
increases in the LUMA-breast cancer association were observed among women who were physically 
active (moderate RPA: OR=2.62; 95% CI=1.44, 4.75 and high RPA: OR=2.62; 95% CI=1.53, 4.49). Es-
timates among obese and inactive women were less pronounced and imprecise. Although we observed 
statistical interactions (p<0.05) between BMI and RPA with LINE-1, we were unable to discern any clear 
associations with breast cancer.  
Conclusions: The association between LUMA and postmenopausal breast cancer risk may be modified 
by postmenopausal body size and physical activity. 









Breast cancer remains the leading cause of can-
cer-related illness in the United States, and is thought 
to be the result of both abnormal genetic and epige-
netic change (1). DNA methylation is an epigenetic 
modification that may influence cancer development 
by altering gene expression and genome integrity (2). 
While gene-specific methylation in target tissue has 
been investigated widely, global hypomethylation in 
peripheral blood DNA has been related to the cancer 
genome (3) and may be a useful surrogate biomarker 
for studying lifestyle or environmental effects in large 
epidemiologic studies where tumor tissue is limited. 
Although global loss of DNA methylation can lead to 
genomic instability, alter gene transcription, and in-
crease mutation rates (4), little is known about how 
modifiable lifestyle factors influence DNA methyla-
tion status of the genome (5).  
Elevated body mass and physical inactivity have 
long been associated with increased risk of postmen-
opausal breast cancer (6,7). Both have been shown to 
be associated with markers of global methylation in 
some studies, likely though their downstream effects 
on hormones and inflammation (8-11). Lifestyle fac-
tors may therefore play an important role in the asso-
ciation between global methylation and breast cancer 
risk.  
The goals of this study were two-fold. We aimed 
to examine potential modification of the global DNA 
methylation-breast cancer association by (1) body size 
and (2) physical activity using two independent, but 
complementary, methods to assess global methylation 
in white blood cell (WBC) DNA: long interspersed 
elements-1 (LINE-1) methylation and the luminomet-
ric methylation assay (LUMA). LINE-1 methylation 
approximates levels in repetitive elements (12) and is 
a commonly used surrogate marker of genome-wide 
DNA hypomethylation (13), while LUMA measures 
levels of 5-mC in the CmCGG motif therefore approx-
imating methylation levels at gene promoters rather 
than the total genome (14). We hypothesized that 
body size/physical activity would modify the associ-
ation between global DNA methylation and post-
menopausal breast cancer risk. To our knowledge, 
this is the first study to systematically address the 
interplay between body size or physical activity, DNA 
methylation and postmenopausal breast cancer risk 
using both LUMA and LINE 1.  
Materials and Methods  
We utilized resources from the case-control 
component of the Long Island Breast Cancer Study 
Project (LIBCSP), a population-based study. Details of 
the parent study have been reported previously (15). 
Institutional Review Board approval was obtained by 
all participating institutions.  
Study population 
LIBCSP participants were English-speaking fe-
male residents of Nassau and Suffolk counties, Long 
Island, New York. LIBCSP case women were newly 
diagnosed with a first primary breast cancer between 
August 1, 1996 and July 31, 1997, and were identified 
through daily or weekly contact with local hospital 
pathology departments. Population-based controls 
were randomly selected using random digit dialing 
for women under age 65 and Health Care Finance 
Administration rosters for women ages 65 and older. 
LIBCSP controls were frequency matched to the ex-
pected age distribution of case women by 5-year age 
groups. At diagnosis/date of identification, partici-
pants were aged 20-98 years, 67% were postmeno-
pausal and 94% were white. 
Interviews were completed for 82.1% (n=1508) of 
eligible cases and 62.8% (n=1556) of controls, and oc-
curred within 3 months of diagnosis (before comple-
tion of the first course of treatment) for most case 
participants (15). At the time of the case-control in-
terview, trained phlebotomists obtained a non-fasting 
40 mL blood sample from 73.1% of case and 73.3% of 
control participants. DNA was isolated from blood 
specimens using the methods previously described 
(16). Written informed consent was obtained from all 
participants prior to the study interview. 
Global Methylation 
LUMA assessment in the LIBCSP has been de-
scribed in detail (14) and followed the modified pro-
tocol described by Bjornsson et al. (17). LUMA levels 
were expressed as a percentage based on the follow-
ing equation: methylation (%) = [1-(HpaII 
ΣG/ΣT)/(MspI ΣG/ΣT)]*100 (17,17). LINE-1 methyl-
ation profiling for the LIBCSP has also been described 
in detail (14). A pre-validated pyrosequencing-based 
methylation assay (18,19) was used to assess 4 CpG 
sites in the promoter region of LINE-1. Methylation 
status at each of the 4 loci were analyzed individually 
as a T/C single nucleotide polymorphism using 
QCpG software (Qiagen) and subsequently averaged 
to provide an overall percentage 5mC status. For 
quality control randomly selected samples were rep-
licated to examine batch effects (corresponding CV% 
<1%). Additionally, cases and controls were assayed 
at the same time with laboratory personnel blinded to 
both case-control and quality control status. 
Body Size, Physical Activity and Covariate 
Assessment 
Body size and physical activity were assessed as 
part of the interviewer-administered structured ques-




tionnaire. Body mass index (BMI) at reference date 
was calculated for each participant based on the fol-
lowing formula: weight (kg)/height (m2). Recreation-
al physical activity (RPA) was assessed using a modi-
fied instrument developed by Bernstein and col-
leagues (20). RPA from menopause to reference date 
was used to estimate postmenopausal physical activ-
ity as previously described (21). 
During the baseline interview participants were 
also asked about their demographic characteristics; 
reproductive, menstrual, environmental, and medical 
histories (including family history of breast cancer); 
cigarette smoking and alcohol use; and use of exoge-
nous hormones.  
Statistical Methods 
All statistical analyses were performed using 
SAS statistical software version 9.1 (SAS Institute, 
Cary, NC).  
 The relationship between LUMA and LINE-1 
global methylation in WBC DNA and breast cancer 
incidence has been previously reported among all 
women in the LIBCSP study population, regardless of 
menopausal status (14). Because this investigation 
focuses on postmenopausal breast cancer only, where 
associations with BMI and RPA are most relevant, we 
first estimated associations between LUMA, LINE-1 
and breast cancer incidence among postmenopausal 
women only.  
We subsequently assessed whether BMI or RPA 
was associated with global methylation levels meas-
ured in the blood of controls only. We conducted un-
conditional logistic regression to estimate odds ratios 
(ORs) and 95% confidence intervals (CI) (22), with 
dichotomous global methylation markers as the out-
come. We additionally used linear regression to esti-
mate the association between BMI or RPA and global 
methylation levels. 
Finally, we used a case-control approach to de-
termine whether the association between global 
methylation (measured by LUMA and LINE-1) and 
postmenopausal breast cancer risk varied within 
strata of BMI or RPA. We conducted unconditional 
logistic regression (22) to estimate ORs and corre-
sponding 95% CIs for the joint effects of: (1) BMI and 
LUMA; (2) RPA and LUMA; (3) BMI and LINE-1; as 
well as (4) RPA and LINE-1, respectively. Multiplica-
tive interaction was assessed by comparing multivar-
iable models with and without cross-product terms to 
represent the interaction between BMI or RPA and the 
individual methylation marker (LUMA or LINE-1) 
using an a priori p<0.05 (23). For case-control analyses 
methylation levels were categorized into quartiles 
based on the distribution among controls. Given 
LUMA, a global measurement of promoter methyla-
tion, was positively associated with overall breast 
cancer risk in our study population (14) we used the 
lowest quartile as the referent group. In contrast, 
LINE-1 hypomethylation is hypothesized to represent 
decreased genomic integrity. Therefore the highest 
quartile of LINE-1 was selected as the referent cate-
gory. We categorized BMI using the standard World 
Health Organization classifications (<25.0 kg/m2; 
25.0–29.9 kg/m2; and ≥30 kg/m2) and RPA based on 
the following definitions: inactive (no RPA), moderate 
RPA (≤9.23 hrs/wk), and high RPA (>9.23 hrs/wk).  
For all models, potential confounders included 
first degree family history of breast cancer (yes/no), 
history of benign breast disease (yes/no), race 
(white/black/other), use of oral contraceptives (ev-
er/never), hormone replacement therapy (ev-
er/never), age at menarche (continuous), parity (con-
tinuous), lactation history (ever/never), age at first 
birth (continuous), age at menopause (continuous), 
total daily calories (continuous), alcohol history (ev-
er/never), and smoking history (never, current, for-
mer). Confounders were included in the final model if 
their inclusion changed the exposure estimate >10% 
(24). None of the above covariates met our criterion 
and final models were adjusted only for 5-year age 
group. 
Results 
Table 1 shows the frequency (%) of the key co-
variates used in our analyses (age, BMI, RPA, LUMA 
and LINE-1) by case control status among LIBCSP 
postmenopausal participants. LUMA levels were as-
sociated with increased risk of postmenopausal breast 
cancer (Quartile 4 [Q4] vs. Quartile 1 [Q1]: OR=2.20; 
95% CI=1.62, 3.00), whereas LINE-1 methylation lev-
els were not (Q4 vs. Q1: OR=0.86; 95% CI=0.64, 1.16).  
In Table 2, we present the association between 
LUMA and postmenopausal breast cancer risk within 
strata of postmenopausal BMI and RPA, respectively. 
The association between LUMA and postmenopausal 
breast cancer risk was stronger among women with 
BMI<25 (OR=2.16; 95% CI=1.35, 3.47) or BMI 25-29 
(OR=2.96; 95% CI=1.69, 5.19), compared to women 
with BMI≥30 (OR=1.46; 95% CI=0.78, 2.73) (multipli-
cative interaction p=0.03). Similarly, the association 
between LUMA and postmenopausal breast cancer 
risk was greater than 2-fold among women with low 
(OR=2.62; 95% CI=1.53, 4.49) and high (OR=2.62; 95% 
CI=1.44, 4.75) RPA, whereas the association among 
inactive women was less in magnitude and included 
the null (OR=1.63; 95% CI=0.86, 3.11) (multiplicative 
interaction p=0.004). 
We observed multiplicative interactions (p<0.05) 
between LINE-1 methylation and both BMI and RPA, 
but our estimates were imprecise and we were unable 




to discern any clear patterns of association (Table 3). 
Furthermore, among control women neither post-
menopausal BMI nor RPA were associated with 
LUMA in logistic or linear regression models (data 
not shown). 
Discussion 
In this population-based case-control study, we 
observed a greater than 2-fold increased risk of post-
menopausal breast cancer when women in the highest 
quartile of LUMA were compared to women in the 
lowest. This association was modified by both BMI 
and RPA. LUMA was associated with the greatest risk 
of postmenopausal breast cancer among women with 
BMI<30 and among women who were physically ac-
tive. Although we observed a significant multiplica-
tive interaction (p<0.05) between LINE-1 and both 
BMI and RPA, we were unable to identify any clear 
relationship. We therefore conclude that, in our data, 
the association between LUMA and postmenopausal 
breast cancer risk is modified by both BMI and RPA.  
To our knowledge, this is the first epidemiologic 
study to examine the association between ge-
nome-wide DNA methylation, assessed using LUMA, 
BMI or RPA and human cancer of any site. Lower 
global methylation can lead to genomic instability and 
changes in gene transcription which may impact 
normal cell growth and increase the likelihood of 
tumorigenesis (25). Given the cost and tissue specific-
ity (26) of whole-genome methylation profiling, global 
methylation levels, assessed by LUMA, in readily 
available specimens (e.g. blood) may be feasible when 
studying lifestyle or environmental effects in large 
populations (27).  
 
TABLE 1. Distributions of key covariates among postmeno-
pausal cases and controls, Long Island Breast Cancer Study Project 
(1996-1997). 
 Cases  Controls 
  No %   No % 
Age at reference (years)a      
<40 12 1.2  15 1.5 
40-44 28 2.8  33 3.3 
45-49 99 9.8  111 11.2 
50-54 179 17.8  201 20.3 
55-59 170 16.9  192 19.4 
60-64 180 17.9  185 18.7 
65-69 184 18.3  123 12.4 
70-74 99 9.8  74 7.5 
75-79 35 3.5  38 3.8 
≥80 80 2.0  18 1.8 
Body mass index (BMI)a      
BMI (<25kg/m2) 386 39.0  439 45.3 
BMI (25-29.9kg/m2) 340 34.3  309 31.9 
BMI (≥30kg/m2) 264 26.7  222 22.9 
Recreational physical activity (RPA)b      
Inactive 254 30.1  223 27.8 
Low RPA (≤ 9.23 hrs/wk) 329 38.9  290 36.1 
High RPA (>9.23 hrs/wk) 262 31.0  290 36.1 
Luminometric methylation assayc      
Quartile 1 (<0.43) 119 17.3  164 24.1 
Quartile 2 (0.43<0.56) 126 18.3  177 26.0 
Quartile 3 (0.56<0.66) 186 27.0  175 25.7 
Quartile 4 (≥0.66) 259 37.5  165 24.2 
Long interspersed elements-1c      
Q4 (≥80.4) 186 26.7  156 22.8 
Q3 (78.7<80.4) 175 25.1  180 26.4 
Q2 (77.0<78.7) 155 22.2  171 25.0 
Q1 (<77.0) 182 26.1   176 25.8 
Adapted from Gammon et al. 2002a; McCullough et al.2012b; and Xu et al.c 
 
TABLE 2. Age-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between the luminometric methylation 
assay (LUMA) methylation levels and postmenopausal breast cancer stratified by postmenopausal body mass index (BMI) and recreational 
physical activity (RPA, average hours per week) among cases (Ca) and controls (Co), Long Island Breast Cancer Study Project 
(1996-1997). 
LUMA (Quartiles) Caa/Cob ORc 95% CId   Ca/Co OR 95% CI   Ca/Co OR 95% CI 
 Body Mass Index     
 BMIe (<25kg/m2)  BMI (25-29.9kg/m2)  BMI (≥30kg/m2) 
Q1 (<0.43) 48/77 1.00 reference   32/50 1.00 reference   38/34 1.00 reference  
Q2 (0.43<0.56) 48/80 0.94 (0.56, 1.56)  41/55 1.18 (0.65, 2.16)  35/40 0.83 (0.43, 1.60) 
Q3 (0.56<0.66) 66/84 1.24 (0.76, 2.02)  62/54 1.82 (1.02, 3.25)  57/35 1.51 (0.80, 2.85) 
Q4 (≥0.66) 98/74 2.16 (1.35, 3.47)  97/51 2.96 (1.69, 5.19)  59/38 1.46 (0.78, 2.73) 
 multiplicative p = 0.033         
 Recreational Physical Activity     
 High RPAf (>9.23 hrs/wk)  Moderate RPA (≤ 9.23 hrs/wk)  Inactive 
Q1 (<0.43) 27/51 1.00 reference  43/54 1.00 reference  31/33 1.00 reference 
Q2 (0.43<0.56) 32/65 0.89 (0.47, 1.69)  44/47 1.16 (0.65, 2.06)  38/38 1.11 (0.57, 2.18) 
Q3 (0.56<0.66) 54/43 2.45 (1.31, 4.59)  51/50 1.27 (0.72, 2.23)  48/43 1.21 (0.63, 2.33) 
Q4 (≥0.66) 72/53 2.62 (1.44, 4.75)  92/46 2.62 (1.53, 4.49)  59/39 1.63 (0.86, 3.11) 
  multiplicative p = 0.004                 
a Cases; b Controls; c Odds ratio; d Confidence interval; e Body mass index; f Recreational physical activity 
 




TABLE 3. Age-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between long interspersed elements-1 
(LINE-1) methylation profiling and postmenopausal breast cancer stratified by postmenopausal body mass index (BMI) and recreational 
physical activity (RPA, average hours per week) among cases (Ca) and controls (Co), Long Island Breast Cancer Study Project 
(1996-1997). 
LINE-1 (Quartiles) Caa/Cob ORc 95% CId   Ca/Co OR 95% CI   Ca/Co OR 95% CI 
 Body Mass Index     
 BMIe (<25kg/m2)  BMI (25-29.9kg/m2)  BMI (≥30kg/m2) 
Q4 (≥80.4) 69/79 1.00 reference   62/50 1.00 reference   51/44 1.00 reference  
Q3 (78.7<80.4) 58/81 1.14 (0.72, 1.79)  47/61 0.64 (0.37, 1.09)  46/26 1.46 (0.77, 2.75) 
Q2 (77.0<78.7) 63/78 0.93 (0.58, 1.47)  63/55 0.95 (0.56, 1.61)  44/45 0.85 (0.47, 1.52) 
Q1 (<77.0) 75/76 1.14 (0.72, 1.79)  60/46 1.10 (0.64, 1.89)  51/33 1.30 (0.71, 2.38) 
 multiplicative p = 0.014         
 Recreational Physical Activity     
 High RPAf (>9.23 hrs/wk)  Moderate RPA (≤ 9.23 hrs/wk)  Inactive 
Q4 (≥80.4) 51/50 1.00 reference  67/48 1.00 reference  46/33 1.00 reference 
Q3 (78.7<80.4) 47/61 0.86 (0.48, 1.54)  60/48 1.07 (0.62, 1.85)  44/42 0.54 (0.29, 1.02) 
Q2 (77.0<78.7) 43/55 0.76 (0.43, 1.34)  55/51 1.27 (0.74, 2.19)  30/39 0.74 (0.41, 1.34) 
Q1 (<77.0) 45/46 1.05 (0.59, 1.86)  50/51 1.42 (0.83, 2.43)  58/41 0.97 (0.53, 1.77) 
  multiplicative p = 0.049                 
a Cases; b Controls; c Odds ratio; d Confidence interval; e Body mass index; f Recreational physical activity 
 
 
A number of investigations have evaluated as-
sociations between biomarkers of global methylation 
and other cancer types, but less is known about the 
effect of global methylation in breast cancer, particu-
larly with LUMA (reviewed in (28)). Delgado-Cruzata 
(29) reported no difference in methylation levels by 
LUMA between affected and unaffected sisters, while 
a recent hospital-based case control study conducted 
in a Japanese population showed breast cancer risk 
reductions with increasing tertiles of LUMA methyla-
tion (30). These results are in contrast to what was 
observed in our study population, namely that 
women in the highest quintile of LUMA had in-
creased risk of breast cancer (OR=2.14; 95% CI=1.83, 
3.16; p trend < 0.0001) compared to women in the 
lowest quintile (14). The same report (14) found no 
association with LINE-1, which is consistent with the 
results of a recent meta-analysis that considered all 
cancer outcomes (28).  
Further, there are inconsistencies in associations 
between both BMI and physical activity with LINE-1. 
Elevated BMI has been shown to be associated with 
lower LINE-1 methylation some studies (8,9) but was 
not correlated with LINE-1 in others (31,32). Regard-
ing physical activity, some studies show associations 
between exercise and LINE-1 (10,11), while others do 
not (33). Given the unclear associations between BMI 
or physical activity and LINE-1, as well as the uncer-
tainty of LINE-1 methylation as a useful biomarker in 
epidemiologic studies of cancer (28), our findings for 
LINE-1 are not unexpected. While our observations 
for LUMA support our a priori hypothesis of modifi-
cation by both BMI and physical activity, we antici-
pated that the positive association between LUMA 
and postmenopausal breast cancer risk would be 
strongest among women with elevated BMI and/or 
inactive lifestyle. On the contrary, our data showed 
that high LUMA levels were more strongly associated 
with enhanced postmenopausal breast cancer risk 
among active women and women with 
BMI<30kg/m2. Obesity/inactivity is associated with a 
myriad of health consequences – many of which may 
not be mediated by changes in DNA methylation. We 
anticipate that our seemingly paradoxical results may 
be because obese women in the lowest quartile of 
LUMA (Q1) are already at enhanced risk of post-
menopausal breast cancer. Any additional risk caused 
by aberrant DNA methylation may therefore be 
minimal. In contrast, women with BMI <25kg/m2 or 
high levels of physical activity have a baseline risk of 
breast cancer that is relatively low (as compared with 
women who are overweight/obese or those with 
lower levels of physical activity). Thus, any additional 
risk caused by aberrant methylation, may be substan-
tial enough to enhance overall susceptibility to post-
menopausal breast cancer among those women who 
are at lower risk of breast cancer. 
Strengths of our study include is its popula-
tion-based design; relatively large sample size; as well 
as detailed exposure assessment. While anthropo-
metric data were collected systematically by trained 
interviewers (15) errors in reporting or differential 
reporting by cases and controls have the potential to 
bias the study results. However, is unlikely that mis-
reporting is differential with respect to methylation 
status (34). While there is interest in identifying epi-
genetic markers in surrogate tissue that could be used 
to identify high risk populations, it is unknown 
whether these markers truly reflect the epignome or 
gene regulation in the target tissue. Some studies in-
dicate that blood-derived DNA methylation meas-
urements (e.g. LINE-1) do not correlate with methyl-




ation in tumor tissue (31,35,36), but additional inves-
tigations are needed to understand the correlation 
between target and surrogate tissues using other as-
says, particularly LUMA.  
Using data from a large population-based sam-
ple, we observed that high methylation levels, as-
sessed via the LUMA, were inversely associated with 
postmenopausal breast cancer among active and 
non-obese women. While our results require confir-
mation, they suggest that body size or physical activ-
ity may play an important role in modifying the asso-
ciation between DNA methylation and postmeno-
pausal breast cancer. Given the plasticity of epigenetic 
marks in response to cancer-related exposures, addi-
tional research is needed to clarify these mechanisms 
and identify specific changes likely to be involved in 
the pathogenesis of breast cancer.  
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